GI
SRPT icon

GAMMA Investing’s Sarepta Therapeutics SRPT Stock Holding History

GAMMA Investing’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$39.9K Sell
2,191
-508
-19% -$9.51K ﹤0.01% 2532
2026
Q2 		$48.5K Sell
2,699
-1,494
-36% -$28.3K ﹤0.01% 2312
2026
Q1 		$91.2K Buy
4,193
+127
+3% +$2.46K ﹤0.01% 1758
2025
Q4 		$87.5K Buy
4,066
+977
+32% +$20.6K ﹤0.01% 1679
2025
Q3 		$59.5K Buy
3,089
+2,288
+286% +$40.8K ﹤0.01% 1867
2025
Q2 		$13.7K Buy
801
+161
+25% +$6.87K ﹤0.01% 2655
2025
Q1 		$40.8K Sell
640
-214
-25% -$22.5K ﹤0.01% 1934
2024
Q4 		$104K Buy
854
+185
+28% +$22.7K 0.01% 1088
2024
Q3 		$83.6K Buy
669
+51
+8% +$7.05K 0.01% 1117
2024
Q2 		$97.6K Buy
618
+296
+92% +$38K 0.01% 794
2024
Q1 		$41.7K Buy
322
+87
+37% +$10.7K 0.01% 1160
2023
Q4 		$28K Buy
+235
New +$22.5K 0.01% 1267

Other funds holding SRPT

AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
MAFA
MJT & Associates Financial Advisory Monteviceo, Minnesota $155M AUM 15.7% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

GAMMA Investing's SRPT Position: Q3 2026 in Review

GAMMA Investing reduced its Sarepta Therapeutics (SRPT) stake by 19% in Q3 2026, selling an estimated $9.51K and leaving 2,191 shares worth $39.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2532.

GAMMA Investing first reported a position in SRPT in Q4 2023 and has held it in 12 quarters since. The position peaked at $104K in Q4 2024. 9 funds tracked by Wall St. Rank hold SRPT as of Q3 2026.

  • GAMMA Investing held 2,191 shares of Sarepta Therapeutics worth $39.9K as of Q3 2026.
  • GAMMA Investing sold 508 Sarepta Therapeutics shares in Q3 2026, an estimated $9.51K.
  • Sarepta Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #2532 holding.
  • GAMMA Investing first reported a position in Sarepta Therapeutics in Q4 2023 and has held it in 12 quarters since.
  • GAMMA Investing's Sarepta Therapeutics position peaked at $104K in Q4 2024.
  • 9 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.